For which condition is a transdermal contraceptive patch not recommended for women over 200 pounds?

For which condition is a transdermal contraceptive patch not recommended for women over 200 pounds?

• A. Deep vein thrombosis
• B. Polycystic ovarian syndrome
• C. Primary dysmenorrhea
• D. Hormone replacement therapy

Answer: (A)

The transdermal contraceptive patch is less effective in women who weigh over 200 pounds due to pharmacokinetic differences that affect the absorption and systemic circulation of hormones delivered through the patch. For women over this weight threshold, the risk of unintended pregnancy increases because the hormone delivery may not reach adequate levels to provide effective contraception. In the case of deep vein thrombosis, while women with a history of this condition should be cautious about using hormonal contraceptives, the key factor leading to the recommendation against using a transdermal patch specifically pertains to effectiveness related to weight rather than an outright contraindication. In contrast, conditions such as polycystic ovarian syndrome, primary dysmenorrhea, or hormone replacement therapy do not have the same weight-related effectiveness issues with the transdermal patch. Therefore, the recommendation against the use of the patch for women over 200 pounds primarily centers around the increased risk of contraceptive failure due to lower hormone levels rather than the presence of another medical condition like deep vein thrombosis.

The transdermal contraceptive patch is less effective in women who weigh over 200 pounds due to pharmacokinetic differences that affect the absorption and systemic circulation of hormones delivered through the patch. For women over this weight threshold, the risk of unintended pregnancy increases because the hormone delivery may not reach adequate levels to provide effective contraception.

In the case of deep vein thrombosis, while women with a history of this condition should be cautious about using hormonal contraceptives, the key factor leading to the recommendation against using a transdermal patch specifically pertains to effectiveness related to weight rather than an outright contraindication. In contrast, conditions such as polycystic ovarian syndrome, primary dysmenorrhea, or hormone replacement therapy do not have the same weight-related effectiveness issues with the transdermal patch.

Therefore, the recommendation against the use of the patch for women over 200 pounds primarily centers around the increased risk of contraceptive failure due to lower hormone levels rather than the presence of another medical condition like deep vein thrombosis.